NCT05674448View on ClinicalTrials.gov

A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and Hepatitis D Co-infection

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

July 25, 2022

Study Completion Date

January 4, 2023

Conditions
Chronic Hepatitis B and Hepatitis D Co-infection
Interventions
BIOLOGICAL

HH-003 20mg/kg

HH-003 20mg/kg Q2W intravenously for 24 weeks

BIOLOGICAL

HH-003 3mg/kg

HH-003 3mg/kg Q2W intravenously for 24 weeks

Trial Locations (1)

130021

First Hospital of Jilin University, Changchun

Sponsors

Lead Sponsor

Huahui Health
All Listed Sponsors
lead

Huahui Health

INDUSTRY

NCT05674448 - A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and Hepatitis D Co-infection | Biotech Hunter | Biotech Hunter